Literature DB >> 15175323

Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin.

Zheming Lu1, Xiuhua Hu, Yong Li, Li Zheng, Yue Zhou, Haidi Jiang, Tao Ning, Zhuoma Basang, Chunfeng Zhang, Yang Ke.   

Abstract

Tuberous sclerosis complex (TSC) is a genetic disorder caused by mutations in either TSC1 or TSC2 tumor suppressor gene. TSC1 and TSC2 products, Harmatin and Tuberin, form the functional complex to serve as the negative regulator for insulin-induced phosphorylation of S6 kinase and elF4E-binding protein 1. High-risk human papillomavirus (HPV) infection is the necessary cause for cervical cancer. E6 oncoprotein encoded by HPV plays a pivotal role in carcinogenesis by interference with the host intracellular protein functions. In this study, we show that HPV16 E6 interacts with tumor suppressor gene TSC2 product, Tuberin, and results in the phosphorylation of S6 kinase and S6 even in the absence of insulin. The overexpression of Tuberin overcomes the effect of E6 on S6 kinase phosphorylation. Binding with HPV16 E6 causes the proteasome-mediated degradation of Tuberin. A DILG motif and an ELVG motif located in the carboxyl-terminal of Tuberin are required for E6 binding. In addition, the Tuberin interaction region in E6 has been mapped in the amino-terminal portion of HPV16 E6, which is different from the binding domain with p53. These results provide a possible link between E6-induced oncogenesis and the insulin-stimulated cell proliferation signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15175323     DOI: 10.1074/jbc.M403385200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  58 in total

1.  mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.

Authors:  Alfredo A Molinolo; Christina Marsh; Mohamed El Dinali; Nitin Gangane; Kaitlin Jennison; Stephen Hewitt; Vyomesh Patel; Tanguy Y Seiwert; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2012-03-12       Impact factor: 12.531

Review 2.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

3.  Metformin impairs the growth of liver kinase B1-intact cervical cancer cells.

Authors:  Xuxian Xiao; Qiongqiong He; Changming Lu; Kaitlin D Werle; Rui-Xun Zhao; Jianfeng Chen; Ben C Davis; Rutao Cui; Jiyong Liang; Zhi-Xiang Xu
Journal:  Gynecol Oncol       Date:  2012-06-24       Impact factor: 5.482

4.  Herpes Simplex Virus is Akt-ing in translational control.

Authors:  Kara L Norman; Peter Sarnow
Journal:  Genes Dev       Date:  2010-12-01       Impact factor: 11.361

5.  The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Jonathan W Neidigh; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

6.  Is focal cortical dysplasia an infectious disease?

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2013-09       Impact factor: 7.500

Review 7.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

8.  A herpesvirus kinase that masquerades as Akt: you don't have to look like Akt, to act like it.

Authors:  Uyanga Chuluunbaatar; Ian Mohr
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

9.  Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.

Authors:  Wei Feng; Xiuzhen Duan; Jinsong Liu; Jianguo Xiao; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

10.  Genetics and molecular biology of tuberous sclerosis complex.

Authors:  Valerio Napolioni; Paolo Curatolo
Journal:  Curr Genomics       Date:  2008-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.